Levi & Korsinsky notifies investors that it has commenced an investigation into Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) concerning potential violations of the federal securities laws.
On July 9, 2025, Ultragenyx issued a press release announcing the randomized controlled portion of the Phase 3 Orbit Study for Osteogenesis Imperfecta is progressing toward final analysts for end of year but stopped short of presenting any interim results. Ultragenyx had “hoped to be able to stop the study early” if positive results were achieved at the interim analysis. Following this news, Ultragenyx’s stock price fell by $10.83 per share to open at $30.61 per share.
If you suffered a loss on your Ultragenyx Pharmaceutical Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





